Arbutus announces a 57% workforce reduction
Source: SeekingAlpha
2025-03-27 09:03:00 ET
More on Arbutus Biopharma
- Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.
- Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
- Arbutus appoints Lindsay Androski as CEO
- Arbutus expects to significantly reduce its net cash burn in 2025
- Seeking Alpha’s Quant Rating on Arbutus Biopharma
Read the full article on Seeking Alpha
For further details see:
Arbutus announces a 57% workforce reduction
Arbutus Biopharma Corporation
NASDAQ: ABUS
ABUS Trading
0.58% G/L:
$4.305 Last:
615,480 Volume:
$4.36 Open:
ABUS Latest News
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
November 13, 2025 07:30:00 am
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 07, 2025 08:00:00 am
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
ABUS Stock Data
$811,607,352
153,282,242
0.14%
53
N/A
Biotechnology & Life Sciences
Healthcare
US
Warminster
